Multiple Myeloma (MM)FGFR3 Clinical Trials

1 recruiting trials·Updated daily from ClinicalTrials.gov

FGFR3 overexpression and activating mutations arise from the t(4;14) translocation present in approximately 15% of myeloma, which also upregulates MMSET/NSD2. t(4;14) defines high-risk myeloma per current risk stratification. Trials investigate selective FGFR3 inhibitors (fisogatinib, erdafitinib) and NSD2 inhibitors targeting the co-activated epigenetic pathway in t(4;14)-positive myeloma.

Match trials to my profile Clinician mode →

Top recruiting

Top recruiting FGFR3 Multiple Myeloma (MM) trials

Ranked by phase and US site count. See all 1 trials matched to your profile →

Phase 4

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Other Multiple Myeloma (MM) biomarkers

Browse other molecular targets with active Multiple Myeloma (MM) trials.

KRAS NRAS TP53 / 17p deletion

← All Multiple Myeloma (MM) clinical trials